Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 5 and last traded at GBX 5.90, with a volume of 143181 shares trading hands. The stock had previously closed at GBX 5.50.
Allergy Therapeutics Stock Up 7.3%
The company’s fifty day moving average is GBX 7.82 and its 200-day moving average is GBX 9.82. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The company has a market capitalization of £373.62 million, a PE ratio of -6.08, a price-to-earnings-growth ratio of -30.70 and a beta of 0.87.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
